ARCA biopharma Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de ARCA biopharma.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como ARCA biopharma no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ABIO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	N/A	-6	-5	-5	N/A
12/31/2023	N/A	-5	-5	-5	N/A
9/30/2023	N/A	-5	-5	-5	N/A
6/30/2023	N/A	-6	-6	-6	N/A
3/31/2023	N/A	-8	-8	-8	N/A
12/31/2022	N/A	-10	-11	-11	N/A
9/30/2022	N/A	-14	-14	-14	N/A
6/30/2022	N/A	-17	-17	-17	N/A
3/31/2022	N/A	-18	-18	-18	N/A
12/31/2021	N/A	-19	-19	-19	N/A
9/30/2021	N/A	-19	-17	-17	N/A
6/30/2021	N/A	-16	-14	-14	N/A
3/31/2021	N/A	-13	-11	-11	N/A
12/31/2020	N/A	-10	-8	-8	N/A
9/30/2020	N/A	-6	-6	-6	N/A
6/30/2020	N/A	-5	-5	-5	N/A
3/31/2020	N/A	-5	-5	-5	N/A
12/31/2019	N/A	-5	-5	-5	N/A
9/30/2019	N/A	-6	-5	-5	N/A
6/30/2019	N/A	-6	-6	-6	N/A
3/31/2019	N/A	-7	-7	-7	N/A
12/31/2018	N/A	-8	-8	-8	N/A
9/30/2018	N/A	-11	-11	-11	N/A
6/30/2018	N/A	-13	-13	-13	N/A
3/31/2018	N/A	-17	-16	-16	N/A
12/31/2017	N/A	-18	N/A	-17	N/A
9/30/2017	N/A	-19	N/A	-17	N/A
6/30/2017	N/A	-19	N/A	-17	N/A
3/31/2017	N/A	-17	N/A	-15	N/A
12/31/2016	N/A	-16	N/A	-15	N/A
9/30/2016	N/A	-15	N/A	-14	N/A
6/30/2016	N/A	-14	N/A	-12	N/A
3/31/2016	N/A	-12	N/A	-11	N/A
12/31/2015	N/A	-11	N/A	-11	N/A
9/30/2015	N/A	-11	N/A	-10	N/A
6/30/2015	N/A	-10	N/A	-9	N/A
3/31/2015	N/A	-10	N/A	-9	N/A
12/31/2014	N/A	-10	N/A	-9	N/A
9/30/2014	N/A	-10	N/A	-9	N/A
6/30/2014	N/A	-9	N/A	-9	N/A
3/31/2014	N/A	-10	N/A	-8	N/A
12/31/2013	N/A	-9	N/A	-5	N/A
9/30/2013	N/A	-7	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de ABIO es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de ABIO crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de ABIO crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de ABIO crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de ABIO crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ABIO se prevé que sea elevada dentro de 3 años.

ARCA biopharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) for approximately $180 million in a reverse merger transaction.

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Oruka Therapeutics entered into a definitive agreement to acquire ARCA biopharma, Inc. (NasdaqCM:ABIO) in a reverse merger transaction.

New major risk - Share price stability

Arca Biopharma, Inc. Announces Executive Changes

ARCA biopharma, Inc., Annual General Meeting, Jan 30, 2024

ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General Counsel

ARCA biopharma, Inc. Appoints James Flynn to Board of Directors

Insufficient new directors

ARCA biopharma, Inc., Annual General Meeting, Dec 15, 2022

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA Biopharma, Inc. Appoints Jacob Ma-Weaver Has Joined Its Board of Directors

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

Insufficient new directors

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma, Inc. Announces Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma, Inc. Announces Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Senior VP recently bought US$113k worth of stock

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

ARCA biopharma, Inc. Provides Update on Aspen-Covid-19 Phase 2B Clinical Trial

Chief Accounting Officer & VP of Finance has left the company

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

New 90-day low: US$3.98

New 90-day high: US$4.93

New 90-day high: US$4.55

ARCA biopharma, Inc. Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA biopharma, Inc. Announces AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

New 90-day low: US$3.81

ARCA biopharma reports Q3 results

New 90-day low: US$4.03

ARCA biopharma, Inc. Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

ARCA biopharma, Inc. Announces Promotion of Debra Marshall to Chief Medical Officer

New 90-day low: US$4.18

ARCA biopharma, Inc. Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

New 90-day low - US$5.34

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento